Cytosorbents Reports Q1 2026 Results; DrugSorb-ATR FDA Submission Delayed to Late 2026/Early 2027
CTSO is trading near its 52-week low of $0.499 (14% above the low).
Summary
Cytosorbents reported a widened net loss for Q1 2026 and continued cash burn, while also announcing a delay in the FDA submission for its key DrugSorb-ATR product to late 2026 or early 2027.
Key Events · Earnings and Guidance · CTSO
-
Q1 2026 Financial Results
Net loss widened to $5.1 million ($0.08/share) from $1.5 million ($0.02/share) year-over-year, primarily due to non-cash foreign currency impacts. Revenue increased 2% to $8.9 million, and adjusted net loss improved to $3.4 million.
-
Continued Cash Burn
Cash and equivalents decreased by $1.4 million to $6.4 million, with a cash burn of $1.1 million in the quarter, further impacting liquidity following previous going concern warnings.
-
DrugSorb-ATR Regulatory Delay
The FDA submission for DrugSorb-ATR (for Brilinta) is delayed to late 2026 or early 2027, as the FDA requested additional mechanistic data, pushing back a critical approval timeline.
-
New DOAC Regulatory Path
The company plans to submit a pre-submission request to the FDA within 30 days for a parallel De Novo application for DrugSorb-ATR to remove DOACs (Eliquis®, Xarelto®), representing a potential new market opportunity.
Analysis · CTSO · Industrial Applications And Services
This 8-K reports Q1 2026 financial results, showing a significant increase in net loss to $5.1 million, primarily due to non-cash foreign currency impacts, despite improvements in adjusted net loss and operating loss. The company also reported a cash burn of $1.1 million for the quarter, reducing its cash position to $6.4 million. Critically, the FDA submission for DrugSorb-ATR (for Brilinta) is now delayed to late 2026 or early 2027, requiring additional mechanistic data, which is a setback for a key product. This comes amidst prior warnings about liquidity and Nasdaq compliance issues, making the continued cash burn and regulatory delay particularly concerning for the company's near-term outlook.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29% of the 1517 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSO was trading at $0.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $35.8M. The 52-week trading range was $0.50 to $1.39. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.